Ixekizumab for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 52-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study

ConclusionsIXEQ4W was associated with rapid and significant improvements in the signs and symptoms of active r-axSpA in Chinese patients at week 16 that were sustained at week 52, with no new safety signals.Trial registration numberClinicalTrials.gov identifier: NCT04285229.
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research